Gland Pharma Rating

Gland Pharma Rating 

GLAND PHARMA Q4FY21 : 18.05.2021

* Net Profit Rs 260 cr (Up 37% YoY)
* Ebitda At Rs 375 cr (Up 31%) ; Ebitda Margin At 40% vs 42%
* R&D Expenditure Was Higher 32% YoY And Stood At 3.9% Of Sales
* Rest Of World Grew 129 % YoY As Company Entered New Markets
* COVID Led Demand Supported Growth And Entry Into Various Markets
* Filed 24 ANDA In FY21 And Received Approval For 32 ANDAS
* Launched 10 SKUs (6 Molecules) In Indian Markets